Themis Bioscience and the Coalition for Epidemic Preparedness Innovations (CEPI) have commenced a Phase I clinical trial of Lassa fever vaccine candidate, MV-LASV.

MV-LASV is based on Themis’ measles vector platform and findings licensed from Institut Pasteur. It is a live attenuated, recombinant, viral vectored vaccine formulated using the backbone of the measles Schwarz virus strain.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Under a global alliance, CEPI will fund the investigational vaccine’s development up to the Phase II completion. The Phase II trial will assess MV-LASV for its clinical safety and immunological data.

The company will also use the CEPI investment to build investigational stockpiles of the vaccine candidate. The stock will be trialled for clinical efficacy during outbreaks.

Themis Bioscience CEO Erich Tauber said: “Themis’ versatile technology platform and our ability to rapidly advance candidates into the clinic has been demonstrated previously through the discovery, development and production of a Phase III-ready vaccine candidate against Chikungunya, as well as our recently announced trial for a novel Zika vaccine.

“Our partnership with CEPI for Lassa fever further validates our capabilities and represents our combined commitment to tackle diseases that remain a public health threat globally.”

The Phase I trial will assess the safety, tolerability and immunogenicity of MV-LASV in 60 healthy adults. The assessments will be carried out following administration of two different dose levels.

Sponsored and led by Themis, the trial is taking place at the Centre for the Evaluation of Vaccination in Antwerp, Belgium.

CEPI Vaccine Development director Dr Melanie Saville said: “This first-in-human trial for Themis’ MV-LASV Lassa candidate is an important first step in its evaluation in the clinic and toward developing an effective vaccine, which will be available to at-risk populations during outbreaks of this deadly emerging infectious disease.”

Earlier this month, the company initiated a Phase I trial of a second-generation Zika vaccine in alliance with the ZIKAVAX consortium.